Bristol Myers Squibb Co. (BMY)
67.31
+0.30
(+0.45%)
USD |
NYSE |
Aug 24, 16:00
67.13
-0.18
(-0.27%)
After-Hours: 20:00
Bristol Myers Squibb Enterprise Value : 170.89B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 170.89B |
| August 20, 2026 | 167.74B |
| August 19, 2026 | 172.11B |
| August 18, 2026 | 168.93B |
| August 17, 2026 | 166.03B |
| August 14, 2026 | 164.39B |
| August 13, 2026 | 166.07B |
| August 12, 2026 | 164.13B |
| August 11, 2026 | 163.94B |
| August 10, 2026 | 166.45B |
| August 07, 2026 | 166.21B |
| August 06, 2026 | 165.04B |
| August 05, 2026 | 163.98B |
| August 04, 2026 | 168.60B |
| August 03, 2026 | 167.74B |
| July 31, 2026 | 167.41B |
| July 30, 2026 | 166.49B |
| July 29, 2026 | 162.90B |
| July 28, 2026 | 163.92B |
| July 27, 2026 | 161.80B |
| July 24, 2026 | 160.84B |
| July 23, 2026 | 159.65B |
| July 22, 2026 | 158.12B |
| July 21, 2026 | 158.47B |
| July 20, 2026 | 156.89B |
| Date | Value |
|---|---|
| July 17, 2026 | 158.08B |
| July 16, 2026 | 157.61B |
| July 15, 2026 | 153.95B |
| July 14, 2026 | 150.33B |
| July 13, 2026 | 155.22B |
| July 10, 2026 | 151.62B |
| July 09, 2026 | 152.36B |
| July 08, 2026 | 151.54B |
| July 07, 2026 | 152.42B |
| July 06, 2026 | 149.82B |
| July 02, 2026 | 152.75B |
| July 01, 2026 | 149.29B |
| June 30, 2026 | 151.70B |
| June 29, 2026 | 155.56B |
| June 26, 2026 | 153.43B |
| June 25, 2026 | 149.08B |
| June 24, 2026 | 148.29B |
| June 23, 2026 | 149.37B |
| June 22, 2026 | 147.67B |
| June 18, 2026 | 146.24B |
| June 17, 2026 | 148.86B |
| June 16, 2026 | 150.17B |
| June 15, 2026 | 150.82B |
| June 12, 2026 | 152.64B |
| June 11, 2026 | 152.17B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 679.08B |
| Eli Lilly & Co. | 1.228T |
| Merck & Co., Inc. | 423.37B |
| Pfizer Inc. | 211.77B |
| AstraZeneca PLC | 541.11B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.316B |
| Revenue (Quarterly) | 12.98B |
| Total Expenses (Quarterly) | 9.665B |
| EPS Diluted (Quarterly) | 1.620 |
| Gross Profit Margin (Quarterly) | 67.95% |
| Profit Margin (Quarterly) | 25.54% |
| Earnings Yield | 6.74% |
| Operating Earnings Yield | 11.57% |
| Normalized Earnings Yield | 9.125 |